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ABSTRACT 
 
Human physical capability is influenced by many environmental and genetic factors, 
and it is generally accepted that physical capability phenotypes are highly polygenic.  
However, the ways relevant polymorphisms combine to influence physical capability 
of individuals and populations are unknown.  Initially, the literature was searched to 
identify associations between 23 genetic polymorphisms and human endurance 
phenotypes.  Next, typical genotype frequencies of those polymorphisms in the 
general population were obtained from suitable literature.  Using probability 
calculations, we found only a 0.0005% chance of a single individual in the world 
having the ‘preferable’ form of all 23 polymorphisms.  As the number of DNA 
variants shown to be associated with human endurance phenotypes continues to 
increase, the probability of any single individual possessing the ‘preferable’ form of 
each polymorphism will become even lower.  However, with population turnover, the 
chance of such genetically gifted individuals existing increases.  To examine the 
polygenic endurance potential of a human population, a ‘total genotype score’ (for the 
23 polymorphisms) was calculated for each individual within a hypothetical 
population of 1,000,000.  There was considerable homogeneity in terms of genetic 
predisposition to high endurance potential, with 99% of people differing by no more 
than seven genotypes from the typical profile.  Consequently, with population 
turnover world and Olympic records should improve even without further 
enhancement of environmental factors, as more ‘advantageous’ polygenic profiles 
occasionally, though rarely, emerge.  More broadly, human potential appears limited 
by the similarity of polygenic profiles at both the ‘elite sport’ and ‘chronic disorder’ 
ends of the performance continuum. 
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INTRODUCTION 
 
Achievement at the limit of human physical performance is exemplified in the 
Olympic Games by elite athletic (track and field specialties) performance, and 
ultimately by Olympic and world records 
(http://www.iaaf.org/statistics/records/index.html).  Human physical performance is 
multifactorial and determined by a range of environmental (physical training, 
nutrition and technological aids) and genetic factors.  For example, heritability 
estimates for the maximal rate of oxygen uptake (a key endurance phenotype) are 
typically around 50% both in sedentary individuals and in terms of their response to 
training (Klissouras, 1971; Bouchard et al., 1986; Fagard et al., 1991; Bouchard et al., 
1998; Bouchard et al., 1999).  This heritability is regarded as primarily due to genetic 
as opposed to non-genetic factors.  Indeed, it has been proposed that endurance 
running ability in the genus Homo evolved about two million years ago (Bramble & 
Lieberman, 2004), possibly including the enlargement of the gluteus maximus muscle 
(Lieberman et al., 2006), implicating a positive natural selection for endurance 
running ability (and thus endurance phenotypes such as the maximal rate of oxygen 
uptake) in the ancestors of modern humans. 
 
In addition to the maximal rate of oxygen uptake, at least two other endurance 
phenotypes (economy of movement and lactate/ventilatory threshold) also contribute 
to the endurance performance phenotype (time taken to travel a given distance) seen 
in elite competition.  Current opinion also includes a fourth, related (but arguably 
discrete) phenotype, namely oxygen uptake kinetics (Jones & Carter, 2000).  While 
the latter two endurance phenotypes listed (lactate/ventilatory threshold and oxygen 
uptake kinetics) are yet to be associated with specific genetic polymorphisms in a 
healthy adult population (and are therefore suitable targets for new association and 
case-control studies), each of the four endurance phenotypes will have genetic 
components, which collectively form the genetics of endurance performance. 
 
To date, over 150 DNA polymorphisms have been associated with some form of 
human physical performance or a health-related fitness phenotype (Rankinen et al., 
2006a).  For many of the polymorphisms associated with human performance, there 
has only been a single positive association with a relevant phenotype.  Notable 
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exceptions to this statement include the polymorphisms of the ACE (angiotensin I 
converting enzyme (peptidyl-dipeptidase A) 1) and ACTN3 (actinin, alpha 3) genes 
that have been studied by several research groups, using a variety of experimental 
designs and population types.  Replication of association with endurance performance 
or an endurance phenotype has occurred for just six polymorphisms (ACE, ACTN3, 
ADRB2 (adrenergic, beta-2-, receptor, surface), AMPD1 (adenosine monophosphate 
deaminase 1 (isoform M)), APOE (apolipoprotein E) and BDKRB2 (bradykinin 
receptor B2)) and replication of the associations reported for all polymorphisms 
associated with human performance would obviously increase confidence in the 
previously reported findings.  These observations are indicative of a field of research 
in its infancy.  Nevertheless, the weight of evidence suggests, and indeed it is widely 
accepted, that physical performance phenotypes are highly polygenic (Rankinen et al., 
2006a; Spurway, 2006). 
 
One issue that has not yet been examined, however, is the way in which the relevant 
polymorphisms combine to influence physical performance potential.  The prediction 
of risk for common complex disease via a combination of relevant polymorphisms has 
recently been addressed in principle (Yang et al., 2005) and using coronary heart 
disease risk as a specific focus (Drenos et al., 2007).  However, such predictions have 
yet to be tested experimentally for clinical use.  In contrast to common diseases, the 
potential applicability of such a combinatory polymorphic approach in elite sport 
would, by definition, focus on probabilities related to the elite end of the human 
physical performance continuum.  However, the probability of individuals carrying 
the ‘preferable’ genotype for each polymorphism linked to endurance (or indeed any) 
performance has not been calculated.  As many of the ‘preferable’ genotypes of 
polymorphisms linked to endurance performance are quite rare (<25% of the 
population) it seems probable that very few individuals will possess the preferable 
genotype for each of even a small number of polymorphisms.  If these ‘perfect’ 
genetic individuals (from an endurance perspective) are very rare, the genetic 
predisposition for endurance of the vast majority of the human population depends on 
the number of advantageous and disadvantageous genotypes they may possess.  
Consequently, the first purpose of this study was to calculate, using current 
knowledge regarding polymorphic associations with endurance performance, whether 
individuals are likely to exist who possess all ‘preferable’ genotypes for endurance.  
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The second purpose was to assess the distribution of genetic endurance potential for 
an entire population, via the generation of a ‘total genotype score’ dependent upon the 
nature and frequencies of all known relevant polymorphisms. 
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METHODS 
 
Overview 
 
Initially, common genetic polymorphisms associated with human endurance 
performance were identified from the literature, and their typical genotype 
frequencies established.  Next, the probability of a given individual having the 
‘preferable’ genotype for each of the polymorphisms linked with endurance 
phenotypes was calculated, and the results also applied to population statistics.  
Finally, in order to examine the human genetic heterogeneity for endurance potential, 
a ‘total genotype score’ (for those polymorphisms linked to endurance phenotypes) 
was calculated for each individual within a hypothetical population, and the 
distribution of total genotype scores examined. 
 
Inclusion and exclusion criteria 
 
Initially, we searched the literature for common genetic polymorphisms (minor allele 
frequency in the general population ≥ 0.01) associated with human endurance exercise 
performance or a related endurance phenotype, either in gene association studies or 
case-control studies between elite endurance athletes and other individuals.  The 
search was primarily based on journals indexed in Medline (a National Library of 
Medicine publication database) using various combinations of key words (e.g. 
genotype, physical fitness, performance).  We also used the most recently published 
human gene map for performance phenotypes (Rankinen et al., 2006a) and searching 
of personal libraries.  For inclusion, a polymorphism needed to show at least one 
statistically significant association with endurance performance or an endurance 
phenotype in healthy Caucasians (data on Caucasians predominate in this field).  We 
felt that this key objective criterion of published statistical significance was consistent 
with other approaches (Rankinen et al., 2006a; Rankinen et al., 2006b) and avoided 
the difficult task of repeatedly passing subjective judgment upon the value of one 
published study versus another at this relatively early stage of research in this field.  
Age and sex were not exclusion criteria, but disease and smoking were.  Rare genetic 
polymorphisms related to severely impaired muscle function were not included in our 
analysis – e.g. muscular dystrophies (Schessl et al., 2006) or disrupted mitochondrial 
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function (Tarnopolsky & Raha, 2005).  This process of literature searching and 
considering published studies against our criteria produced a list of 23 polymorphisms 
eligible for further analysis. 
 
Following these objective criteria may have led to the inclusion of some 
polymorphisms that are controversial.  For example, some studies have found an 
association between the R577X polymorphism of the ACTN3 gene and elite 
endurance athlete status (Yang et al., 2003; Niemi & Majamaa, 2005), whilst three 
more recent studies reported no evidence of an association with endurance (Lucia et 
al., 2006; Moran et al., 2007; Paparini et al., 2007).  Nevertheless the ACTN3 R577X 
polymorphism meets our criterion of at least one published statistically significant 
association with endurance performance or an endurance phenotype, and 
consequently it was included in our analysis. 
 
Another key decision was not to include some polymorphisms because the reported 
associations with endurance phenotypes were based on studies that did not use 
healthy, non-smoking, Caucasian adults as participants.  For example, the G-174C 
polymorphism of the IL6 gene has been strongly associated (P = 0.002) with an 
endurance phenotype in smokers (Ortlepp et al., 2003), but in the same study there 
was no association between that polymorphism and the endurance phenotype within a 
comparable group of non-smokers (P = 0.937).  Thus, the IL6 G-174C polymorphism 
may interact with smoking practices to influence physical endurance, but does not 
appear relevant to our analysis of endurance phenotype in healthy, non-smoking, 
Caucasian adults and therefore was not included in our analysis. 
 
Typical genotype frequencies 
 
Data regarding typical genotype frequencies within the 23 polymorphisms in the 
general population were obtained from suitable literature, generally using the studies 
with the largest samples.  Data from Caucasian populations were again used - 
primarily UK Caucasians for consistency, occasionally other European (and European 
descent) populations.  In some cases, the typical frequency data were obtained from 
the same study that provided the statistically significant association with endurance 
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because that study provided the largest, most appropriate, or even the only source of 
typical frequency data. 
 
Occurrence of individuals with an ‘optimal’ polygenic profile for endurance 
 
What is the probability of an individual having the ‘optimal’ polygenic profile for 
endurance?  To answer this question, we calculated the probability of any given 
individual possessing every ‘optimal’ genotype for 1 up to all 23 polymorphisms.  We 
selected the polymorphisms in the alphabetical sequence of their official symbols as 
recommended by the Human Gene Nomenclature Committee (HGNC), which, though 
arbitrary, ultimately did not notably bias the results.  Then, based on the typical 
frequencies of the ‘optimal’ genotypes, we produced a scale of decreasing probability 
that any given individual will possess an increasing number of ‘optimal’ genotypes. 
 
Applying data to population statistics 
 
The probability data for the occurrence of individuals with ‘optimal’ genetic potential 
were then related to population statistics.  Hence, we predicted the number of 
individuals with a given number of optimal genotypes, or indeed the probability that 
one individual exists, in a medium-sized nation (e.g. 60 million in the UK 
(http://www.statistics.gov.uk/cci/nugget.asp?id=6)) and the 6.5 billion world 
population (http://www.census.gov/ipc/www/idb/worldpopinfo.html).  Using the 
polymorphisms selected in sequence of their official HGNC symbols, we applied our 
data to every possible number of polymorphisms from 1-23.  As the probability of 
even a single individual possessing a large number of selected optimal genotypes was 
so low, we also calculated the probability that an individual possesses any 22 of the 
23 optimal genotypes and then extended that to any 21 of the 23. 
 
Polygenic potential for endurance of a whole population 
 
To examine the genetic potential for endurance of all individuals in a wider 
population (rather than just the upper extreme of the population, as in the previous 
sections), it was first necessary to allocate scores to each genotype within a particular 
polymorphism.  Typically, the polymorphisms identified were bi-allelic, providing 
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three possible genotypes.  The homozygote genotype associated with the better 
endurance phenotype was given a ‘score’ of 2, with a linear trend applied such that 
the heterozygotes were scored 1 and the other homozygotes, 0.  In studies including 
only homozygotes (e.g. Williams et al. (Williams et al., 2000)), heterozygotes were 
given an intermediate score of 1.  For the APOE polymorphism there are three alleles, 
and thus six genotypes.  Based on two studies (Hagberg et al., 1999; Thompson et al., 
2004), the ‘optimal’ APOE allele for endurance phenotypes was determined as E4, so 
E4/E4 and E3/E4 scored 2, E3/E3 and E2/E4 scored 1, E2/E2 and E2/E3 scored 0.  
For the four mitochondrial DNA polymorphisms (Dionne et al., 1991), there were 
only two possible morphs in each case, scored 2 or 0.  The maximum and minimum 
available values were chosen for the mitochondrial DNA polymorphisms to ensure 
equivalent weighting to the chromosomal polymorphisms.  The genotype scores 
allocated to each polymorphism can be viewed in the Supplemental Material. 
 
To quantify the combined influence of all 23 polymorphisms currently associated 
with endurance phenotypes, an algorithm was created to incorporate all 23 genotype 
scores for any given individual in a simple additive model.  The total score was then 
transformed mathematically to lie within the range 0-100 (to be intuitively 
meaningful) and labelled the ‘total genotype score’ (TGS).  Considering the 23 
genotype scores GS1, GS2 … GS23, the TGS can be calculated as: 
 
TGS = (100/46) x (GS1 + GS2 + … + GS23) 
 
A TGS of 100 represents a ‘perfect’ polygenic profile for endurance and a TGS of 0 
represents the ‘worst’ possible profile for endurance.  The word ‘perfect’ is, of course, 
only to be interpreted within the context of this paper – when other polymorphisms 
are shown to be associated with endurance in the future, as we strongly expect, the 
‘perfect’ profile will of course change (and actually become less likely to occur 
spontaneously).  To examine the nature of the distribution of total genotype scores in 
the general population, we created a data set of 1,000,000 hypothetical individuals, 
each with a randomly generated genetic profile (for all 23 polymorphisms) based on 
the typical frequency of each genotype.  Finally, we evaluated the distribution of 
TGSs within this population, and calculated the degrees of kurtosis and skewness 
using the ‘Descriptives’ facility within the statistical software package SPSS (v.11). 
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RESULTS 
 
The complete list of the 23 polymorphisms associated with endurance phenotypes, 
including full names, typical genotype frequencies and the sources of all information, 
can be accessed in the Supplemental Material.  The list in alphabetical order of the 
official HGNC symbols is also shown in Table 1. 
 
Occurrence of individuals with an ‘optimal’ polygenic profile for endurance 
 
For the 23 polymorphisms identified, typical genotype frequencies in the general 
population ranged from 1% (for the TT genotype of the AMPD1 gene (Rico-Sanz et 
al., 2003) found on chromosome 1) to 93% (for some mitochondrial DNA morphs 
(Dionne et al., 1991)).  The typical frequency of the ‘optimal’ genotype of each 
polymorphism is shown in column 3 of Table 1.  Given those data, how likely is it 
that a given individual possesses a ‘perfect’ genetic profile for a given number of 
polymorphisms?  Considering one polymorphism only (ACE I/D (Williams et al., 
2000)), the optimal genotype for endurance performance (II) has a typical frequency 
of approximately 21% in the wider Caucasian population (Mastana et al., 2003).  If a 
second gene (ACTN3 (Yang et al., 2003)) is also considered, an individual’s 
probability of possessing the optimal ACE and ACTN3 (XX genotype; ~18% typical 
frequency) genotypes is already considerably reduced to approximately 4%.  Adding a 
third gene (ADRA2 (Wolfarth et al., 2000)) with a typical frequency of the optimal 
genotype (6.7/6.7) of about 62% further reduces an individual’s chance of possessing 
all three optimal genotypes to just 2%.  The probability of a given individual 
possessing all optimal genotypes continues to decrease exponentially until, when all 
23 polymorphisms are considered, the probability is just 8.2 x 10-14 %, an enormous 
odds ratio of 1 in 1,212 trillion (Table 1). 
 
Applying data to population statistics 
 
Applying the probabilities calculated via the typical frequencies to population 
statistics, we calculated that there is just a 0.0005% (1 in 200,000) probability that 
even a single individual exists in the world possessing the optimal DNA variant for 
endurance performance of all 23 polymorphisms.  The probability only increases to 
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approximately 0.1% when seeking an individual with any 22 of the 23 optimal 
genotypes, and the odds ratio (about 1 in 1,000) still strongly suggests that no such 
individual exists.  When any 21 of the 23 optimal genotypes are included, the 
probability is approximately 10% that an individual exists somewhere in the world 
with such a genetic profile. 
 
When considering a medium-sized nation (e.g. the approximately 60 million 
population of the UK), there is only a 0.000005% (1 in 20 million) chance that an 
individual exists with all 23 optimal DNA variants.  Even for any 21of the 23 optimal 
genotypes, the probability of an individual existing remains low at just 0.1%.  Figure 
1 shows the exponential relationship between the number of genotypes selected as 
important for endurance and the number of people required to expect one individual 
to have a ‘perfect’ genetic profile.  In the UK, we would expect to find a few 
individuals with a selected 12 of the 23 optimal genotypes, but probably no 
individuals with 13 or more.  In the world, we would expect to find a few individuals 
with a selected 16 of the 23 optimal genotypes, but probably no individuals with 17 or 
more. 
 
Polygenic potential for endurance of a whole population 
 
As the probability of an individual possessing a large number of optimal genotypes 
for endurance performance appeared strikingly low, we examined the distribution of 
total genotype scores (TGSs) in a population, using the algorithm we developed 
where each individual was allocated a TGS between 0-100.  The distribution of the 
total genotype scores was leptokurtic, i.e. significantly clustered towards the middle 
(see Figure 2).  In fact, approximately 99% of individuals had a TGS of 37-65, 
towards the centre of the possible range of 0-100 (the mean TGS was 50.8).  The TGS 
range of 37-65 indicates that 99% of individuals differed by no more than seven 
genotype scores from the average, demonstrating extremely similar genetic profiles.  
Furthermore, the total range of TGSs was 22-85, indicating that all individuals 
differed by at least six genotype scores from the theoretical ‘best’ or ‘worst’ 
polygenic profiles.  It appears that the potential for an individual to possess a ‘perfect’ 
or ‘near-perfect’ genetic profile for endurance performance is limited by the clustered 
distribution of total genotype scores.  This clustered distribution is a product of the 
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polygenic nature of endurance performance, but is accentuated by the low typical 
frequencies of some of the optimal genotypes.  For example, six of the optimal 
genotypes had typical frequencies < 10%. 
 
Readers can see the genetic profiles of almost limitless individuals created on demand 
by accessing the Supplemental Material.  Selecting a blank cell in the spreadsheet and 
then pressing ‘delete’ will generate novel genetic profiles for 1,000 randomly 
generated individuals.  If a reader sees a TGS of 100 in column AV on the 
spreadsheet, then an extreme genetic profile (extremely gifted) in terms of endurance 
performance has been created.  The nature of the distribution of TGSs means that it is 
extremely unlikely any reader will see a score of 100, or even a score above 90. 
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DISCUSSION 
 
The main finding of this study is that it is extremely unlikely that even a single 
individual in the world possesses what could be termed a ‘perfect’ polygenic profile 
for endurance.  Nor, indeed, is it at all likely that a ‘near-perfect’ polygenic profile for 
endurance exists in a single individual.  These observations are based on the current 
state of published evidence regarding the relevant genes and polymorphisms in the 
Caucasian population (the population for which there is the most published 
information).  Given the sizeable contribution of genetic factors to human endurance 
(Bouchard et al., 1998; Bouchard et al., 1999; Rankinen et al., 2006a; Spurway, 
2006), this suggests that there is significant further genetic potential in our species 
(i.e. that would not require de novo mutations) for endurance performance that is, as 
yet, unrealised in a single organism.  This view concurs with that provided via a pre-
human genome modelling approach that predicted a best possible marathon time 
(about 1 hour 58 minutes) nine minutes quicker than the world record of the day 
(Joyner, 1991).  In 2007 the world record remains seven minutes slower than that 
predicted best possible time.  The second important finding of this study is that using 
a genetic algorithm, for the first time it has been demonstrated that the polygenic 
nature of human endurance constrains the genetic endurance potential of humans 
within rather narrow upper and lower limits. 
 
Our novel genetic algorithm provides a total genotype score (TGS) of 0-100 to 
indicate genetic potential for endurance.  If individuals really exist with TGSs > 90 
according to our algorithm, are they (or have they been) elite endurance athletes?  
Several studies have used a case-control design to associate a total of 10 genes (ACE 
(Gayagay et al., 1998), ACTN3 (Yang et al., 2003), ADRA2A (Wolfarth et al., 2000), 
ADRB2 (Moore et al., 2001), AMPD1 (Rubio et al., 2005), BDKRB2 (Williams et 
al., 2004), EPAS1 (Henderson et al., 2005), HFE (Chicharro et al., 2004), PPARA 
(Ahmetov et al., 2006), PPARGC1A (Lucia et al., 2005)) directly with some degree 
of ‘elite’ endurance athlete status, although these discrete associations tend to be quite 
weak and a maximum of just two genes (and up to just three polymorphisms) has 
been reported in a single study.  Accordingly, it would be interesting to establish 
whether truly elite endurance athletes (e.g. Olympic medal winners) really do have an 
advantageous genetic profile across a larger number of polymorphisms – e.g. for a 
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large proportion of the 23 polymorphisms used in our analysis.  Our data put the 
probability of this occurring into perspective.  In the entire world, there is 
approximately a 1 in 10 probability that an individual exists with any 21 of the 23 
optimal genotypes.  Given the additional requirement for appropriate environmental 
factors such as nutrition, economics and culture, the data presented here suggest it is 
extremely unlikely that any individuals - even elite endurance athletes - possess nearly 
all of the ‘optimal’ genotypes identified in our analysis.  Precisely how close to the 
maximum figure of 23 elite endurance athletes are remains unknown. 
 
As yet unanswered questions that impact upon the interpretation of the data presented 
here include (i) whether the 23 polymorphisms identified are true genotype-endurance 
phenotype associations that will be replicated by future work, and (ii) whether these 
23 polymorphisms include all or only some of the genetic factors that influence 
human endurance capacity. Clearly, replications of genotype-phenotype associations 
are important given the preliminary nature of many of the associations established to 
date (Chanock et al., 2007). Considering the early stage of this research, future work 
may strengthen confidence in the associations of some polymorphisms we have 
included and fail to replicate those of others. However, based on the premise that 
endurance performance is polygenic in nature, the broad conclusions of this work 
would not be effected by a small decrease in the number and exact polymorphisms 
related to endurance performance. It may be (though we think it extremely unlikely) 
that no further polymorphisms will ever be shown to be associated with human 
endurance, in which case the 23 polymorphisms (if confirmed via replication) account 
for all the heritability of endurance.  If this were the case, the data we have presented 
can be taken literally, in perpetuity.  However, we are extremely confident in 
predicting that many additional polymorphisms will be shown to be associated with 
endurance performance or an endurance phenotype and that the 23 polymorphisms 
identified to date constitute only a fraction of the genetic factors that influence human 
endurance.  In this extremely likely scenario, the probability that even a single 
individual exists who possesses the optimal DNA variant for endurance performance 
of all relevant polymorphisms will reduce far below the 0.0005% value calculated in 
this study.  The odds ratio of a given individual possessing all optimal genotypes will 
become even greater than the 1 in 1,212 trillion calculated, and the distribution of 
total genotype scores will probably become even more leptokurtic.  Hence, the 
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principles underlying our calculations and results will still apply, as will the 
implications for athletic performance – in fact, the principles we have demonstrated 
will become quantitatively even more important.  The perfect genetic profile for 
endurance will remain extremely unlikely to occur spontaneously. 
 
Similarly, the quantitative contribution to human endurance of each of the 23 
polymorphisms identified thus far is unknown.  It is likely that some polymorphisms 
account for a sizeable proportion of the interindividual variation in endurance 
phenotypes, whereas others contribute substantially less, and this will doubtless be 
elucidated as our knowledge evolves.  For example, gene-gene interactions may occur 
via which certain polymorphisms may modify the influence of other genes, under 
certain conditions.  Common sense dictates that, where many genes in a given 
biochemical pathway are each associated with endurance, the contribution of each of 
them may alter in the presence of the optimal form of several of the others.  In 
addition, relevant polymorphisms may be in linkage disequilibrium and thus the 
presence of one optimal genotype may occur more or less often than predicted with 
the presence of other optimal genotypes.  However, neither gene-gene interactions nor 
linkage disequilibria have been demonstrated clearly between the 23 polymorphisms 
identified in this study.  Furthermore, this area of uncertainty again does not affect the 
principles underlying our calculations and results, nor the broad implications for 
Olympic-level athletic performance – high endurance will still be associated with the 
possession of a high proportion of optimal genotypes.  In practice, however, future 
algorithms will probably include appropriate weighting factors that place 
greater/lesser emphasis on particular polymorphisms, as that knowledge becomes 
available. 
 
When viewing Olympic and world records in athletic events as indicators of the limits 
of human physical potential, it should be recognized (as alluded to previously) that a 
performance record is a function of economic and social opportunity in addition to 
genetic potential and physical environment.  For example, the large populations of 
India and China may contain individuals with the genetic potential to rewrite the 
record books, yet this pool of talent has been largely under-represented at elite levels 
of athletics to date (Sharp, 2004).  However, even that increase in size of the talent 
pool would be modest compared to the overall increase that will occur with 
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population turnover.  New births during the passage of time are the most likely means 
of producing individuals extremely genetically gifted for endurance performance.  
Consequently, world records should continue to advance, although probably at a 
steadily reducing rate, purely through an ever-increasing pool of participants.  Any 
advances in relevant technology, physical training, nutrition, etc., will further progress 
the records, but even if these factors remain at their current levels then, ceteris 
paribus, Olympic and world records should continue to improve. 
 
Individuals from a relatively small geographic area hold many world athletic records.  
Indeed, there are considerable regional and ethnic variations in typical frequencies of 
many genotypes – for example, the II genotype of the ACE I/D polymorphism has a 
higher frequency in some regions of Oceania than in most of Europe (Kyle et al., 
2001).  Athletes of north and east African descent excel in endurance events while 
athletes of west African descent excel in sprint events.  However, the possibility of a 
genetic explanation has yet to be supported by research evidence (Pitsiladis & Scott, 
2005), and may in fact be secondary to socio-economic factors.  Nevertheless, the 
medal tables at Olympic and World athletic competitions are at times compelling in 
their composition, and it would be fascinating to establish whether Kenyan, Ethiopian 
and Moroccan populations have generally lower total genotype scores according to 
our algorithm which includes the 23 polymorphisms currently associated with human 
endurance. 
 
The clustered nature of the total genotype scores in our analysis (Figure 2) also means 
that the existence of individuals with large numbers of ‘unfavourable’ genotypes is 
also extremely unlikely.  This is probably advantageous to our species, as morbidity 
and mortality associated with low aerobic fitness (Lee et al., 1999) and chronic 
disorders would likely prevail in such individuals.  Accordingly, continued research 
into the polygenic nature of health-related phenotypes such as aerobic function may 
reveal the lower bounds of genetic potential for endurance that constitute a sufficient 
risk of common complex diseases to warrant individualised lifestyle or 
pharmaceutical interventions.  In that context, it may be interesting to speculate how 
the pressure of natural selection against alleles associated with low endurance 
capability over recent millennia may be reduced with continued advances in society, 
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technology and healthcare systems, which could eventually broaden the polygenic 
distributions we have described, in the future. 
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SUPPLEMENTAL MATERIAL 
 
There is a data supplement that is a database in Microsoft Excel format comprising a 
list of the 23 polymorphisms included, the genotype scores allocated to each genotype 
within each polymorphism, their typical frequencies in the general population and the 
sources of all data.  The database can be used to generate novel polygenic profiles for 
1,000 hypothetical individuals at a single keystroke and contains an algorithm which 
calculates the total genotype score (TGS).  Please see file “Supplemental 
material.xls”. 
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FIGURE LEGENDS 
 
FIGURE 1.  Population size required to find a ‘perfect’ genetic profile, by 
number of polymorphisms 
 
Large graph shows the population size required to expect one individual to have a 
‘perfect’ genetic profile of up to 23 polymorphisms.  For < 19 polymorphisms, the 
bars exist (number of people < 1.7 x 1013) but are too small to be visible.  Therefore, 
the inset shows the same data on a log scale, with UK and world population levels 
identified.  The population sizes required to expect one individual to have all 23 
optimal genotypes clearly exceed UK and even world levels. 
 
 
 
 
FIGURE 2.  Frequency distribution of total genotype scores 
 
Frequency distribution of total genotype scores derived from a model sample of 
1,000,000 randomly generated individuals.  Mean score = 50.8, standard deviation = 
6.2.  The distribution is leptokurtic (i.e. clustered towards the middle; kurtosis statistic 
2.5, standard error 0.7; via SPSS v.11), demonstrating that most humans are 
extremely similar, and thus limited, in terms of their genetic potential for endurance 
performance.  The existence of individuals with very low or very high total genotype 
scores is clearly restricted, suggesting that any outliers that do exist are extremely 
unusual individuals. 
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TABLE LEGENDS 
 
 
TABLE 1.  Probability of ‘perfect’ genetic profile by number of polymorphisms 
 
There is an exponential decrease in the probability of an individual possessing a 
‘perfect’ genetic profile as the number of polymorphisms included increases.  The 
probability of any given individual possessing a high number of genotypes optimal for 
endurance performance is extremely slim.  * repeated entries of a gene reflects the 
inclusion of more than one polymorphism of that gene. 
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TABLE 1.  Probability of perfect genetic profile by number of polymorphisms 
 
 
Number of 
polymorphisms 
influencing 
endurance 
performance 
New gene 
included at 
each stage 
Typical 
frequency of 
optimal 
genotype (%) 
Probability of possessing a ‘perfect’ profile 
% chance Approximate odds ratio 
1 ACE 21 21.0 1:5 
2 ACTN3 18 3.78 1:25 
3 ADRA2 62 2.34 1:40 
4 ADRB2 35 0.82 1:120 
5 AMPD1 80 0.66 1:150 
6 APOE 24 0.16 1:600 
7 ATP1A2* 81 0.13 1:800 
8 ATP1A2 5 6.4 x 10-3 1:16,000 
9 BDKRB2 15 9.6 x 10-4 1:100,000 
10 CKM 49 4.7 x 10-4 1:200,000 
11 EPAS1* 33 1.5 x 10-4 1:600,000 
12 EPAS1 19 2.9 x 10-5 1:3 million 
13 HFE 4 1.2 x 10-6 1:85 million 
14 HIF1A 77 9.1 x 10-7 1:110 million 
15 HLA-A 2 1.8 x 10-8 1:5.5 billion 
16 MT-ND5* 93 1.7 x 10-8 1:6 billion 
17 MT-ND5 7 1.2 x 10-9 1:85 billion 
18 MT-ND5 7 8.3 x 10-11 1:1.2 trillion 
19 MT-TT 7 5.8 x 10-12 1:17 trillion 
20 PPARA 70 4.0 x 10-12 1:25 trillion 
21 PPARGC1A 40 1.6 x 10-12 1:62 trillion 
22 UCP2 17 2.7 x 10-13 1:364 trillion 
23 VEGFA 30 8.2 x 10-14 1:1,212 trillion 
 
